2076975 2077203
최종편집 2024-06-18 17:24 (화)
Tecvayli attains nod for treating multiple myeloma in Korea
상태바
Tecvayli attains nod for treating multiple myeloma in Korea
  • Hyeokgi Lee, Newsmp
  • 승인 2023.08.01 23:26
  • 댓글 0
이 기사를 공유합니다

[Newsmp] The Ministry of Food and Drug Safety approved the orphan drug Tecvayli (ingredient: teclistamab) for the treatment of multiple myeloma on July 26.

Multiple myeloma is a type of blood cancer that occurs when plasma cells, a type of white blood cell that helps the immune system, abnormally divide and multiply in the bone marrow.

As a monoclonal antibody, Tecvayli is used in adult patients with relapsed or refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Tecvayli specifically targets and binds to BCMA (B-cell maturation antigen) antigens on cancer cells. It binds to CD3 proteins present on T cells, activating the immune system to effectively eliminate cancer cells.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.